Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL7130457 | 1.00 | TP53 (1.00) | — | |
| Diethylamine SCHEMBL3558785 | 1.00 | — | — | |
| Diethylamine SCHEMBL2698 | 1.00 | — | — | |
| Diethylamine SCHEMBL3520371 | 0.94 | — | — | |
| Diethylamine SCHEMBL21980959 | 0.94 | — | — | |
| Diethylamine SCHEMBL5051715 | 0.94 | — | — | |
| Diethylamine SCHEMBL21585568 | 0.94 | — | — | |
| Diethylamine SCHEMBL21585566 | 0.94 | — | — | |
| Diethylamine SCHEMBL9289074 | 0.94 | TP53 (0.89) | — | |
| Diethylamine SCHEMBL1514723 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051654-A1 | Treatment of inflammatory and autoimmune diseases | ELLIOTT PETER J (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1017398-A1 | PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-KB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES | PROSCRIPT, INC. (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015183-A9 | PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES | PROSCRIPT INC (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999015183-A1 | PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES | PROSCRIPT INC. (US) | 1999-04-01 | — | — | WO | disclosed |